SCSilvio Caccia

Silvio Caccia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Silvio Caccia has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Alessandro Nobili

    Laboratory of Pharmacoepidemiology and Human Nutrition, Department of Health Policy, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy

    2 shared publications
  • Luca Pasina

    Health Policies Research Department, Laboratory of Clinical Pharmacology and Appropriateness of Drug Prescription Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan Italy

    2 shared publications
  • Alessandro Nobili

    Laboratory of Quality, Assessment of Geriatric Therapies and Services, “Mario Negri” Institute for Pharmacological Research, Milan, Italy

    1 shared publication
  • Antonio Clavenna

    Laboratory of Child Health and Development Epidemiology, Department of Medical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

    1 shared publication
  • Luca Pasina

    Laboratory of Quality, Assessment of Geriatric Therapies and Services, “Mario Negri” Institute for Pharmacological Research, Milan, Italy

    1 shared publication
  • Marco Gobbi

    Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

    1 shared publication

Latest Publications

  • Open Access

    A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia

    by Silvio Caccia, Roberto William Invernizzi, Alessandro Nobili, Luca Pasina

    Peer reviewed article authored by (Caccia S, Invernizzi RW, Nobili A, Pasina L). Read article or submit your manuscript for publishing.


  • Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents

    by Silvio Caccia

    Pediatric behavioral and affective disorders often require antipsychotic therapy, in combination with psychotherapeutic interventions, for their treatment and stabilization. Although pharmacotherapy can include either typical or atypical antipsychotics, the latter are generally preferred because of their apparently lower risk of adverse effects. Recent controlled trials have demonstrated the efficacy of some of these agents (including aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) in adolescent schizophrenia and children or adolescent bipolar mania, or to treat severe aggression and self-injury in the context of autism in children and adolescents. Although few studies have systematically monitored their short- and, more importantly, long-term safety, current evidence indicates that sedation, hyperprolactinemia, and metabolic abnormalities such as excess weight gain, diabetes, and related cardiovascular effects were clinically relevant adverse effects in young patients, with the individual agents differing in their propensity to induce these effects. When prescribing antipsychotics for children and adolescents, physicians should therefore be aware of the specific adverse effect profiles and patients should be closely monitored for the short- and long-term development of adverse events. In pediatric patients, the starting dose, titration plan, and maintenance dose of antipsychotics must be based on their pharmacokinetics and metabolism, as in adults. Because there are significant individual differences in drug and active metabolite(s) pharmacokinetics and metabolism, which may be further affected by a number of confounding factors (including demographic variables, phenotype and drug interactions), therapeutic drug monitoring may be a valid tool for individualizing dosage, but its interpretation should also take account of changes in pharmacodynamic sensitivity with the development during childhood and adolescence.


  • Pharmacokinetics and metabolism update for some recent antipsychotics

    by Silvio Caccia

    (2011). Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opinion on Drug Metabolism & Toxicology: Vol. 7, No. 7, pp. 829-846. doi: 10.1517/17425255.2011.575061


  • Antipsychotic drug toxicology in children

    by Silvio Caccia, Antonio Clavenna, Maurizio Bonati

    Introduction: There is an increasing use of antipsychotic drugs, particularly those of second- and third-generation, for a wide range of behavioral and affective disorders in pediatric and psychiatric practice. Limited data are available, however, regarding their safety and effectiveness, although children may be more vulnerable than adults to antipsychotic adverse effects because of developmental physiological changes that may affect their pharmacodynamic and pharmacokinetic profiles. Areas covered: This review covers the antipsychotics now specifically approved in major markets for children as well as those that are used in these patients for unapproved or off-label indications taking into account the potential differences in drug disposition and metabolism among children, adolescents and adults. MEDLINE and EMBASE international databases were searched for studies concerning the pharmacokinetics, efficacy and safety of first-, second- (‘atypical’) and third-generation antipsychotic agents. Expert opinion: Few studies have systematically monitored the safety of antipsychotics in young populations. Data concerning long-term side effects are especially limited, and a systematic benefit–risk evaluation is needed. When prescribing antipsychotics, physicians should, therefore, monitor patients closely for metabolic adverse events, hyperprolactinemia, extrapyramidal symptoms and corrected QT prolongation. Dose selection should include a careful consideration of the drugs' pharmacokinetic profiles and, when these are lacking therapeutic drug monitoring should be implemented as it is often a valid tool to optimize pediatric psychiatric practice.


  • Open Access

    New atypical antipsychotics for schizophrenia: iloperidone

    by Silvio Caccia, Luca Pasina, Alessandro Nobili

    Peer reviewed article authored by (Silvio Caccia, Luca Pasina, Alessandro Nobili). Read article or submit your manuscript for publishing.


  • St. Johns Wort Components and the Brain: Uptake, Concentrations Reached and the Mechanisms Underlying Pharmacological Effects

    by Silvio Caccia, Marco Gobbi

    Hypericum perforatum L. (St. Johns wort) extracts have gained popularity as an alternative to conventional antidepressant drugs for mild to moderate forms of depressive disorders. New potential psychiatric uses for extracts in obsessive-compulsive disorder, generalised anxiety disorder and alcohol dependence have also been suggested on the basis of animal studies. The neurochemical mechanisms of these central actions are still debated but several components have antidepressant-like and anxiolytic-like effects in animals, or interact with neurotransmitter systems believed to be causally involved in depression, anxiety and in psychiatric illness generally. However, these data should interpreted taking account of the pharmacokinetic data on the main components, particularly those of their brain distribution and concentrations and the relationships with blood concentrations; the (scant) data so far suggest that the acylphloroglucinol hyperforin, the flavonol quercetin and its glycosylated forms and their metabolites, the biflavones amentoflavone and its I3,II8-analog biapigenin and the naphthodianthrones hypericin and pseudohypericin pass the blood-brain barrier poorly in animals. The brain concentrations of all these high-molecular weight, poorly water-soluble compounds after pharmacologically effective doses of the extracts are therefore far below those effective on neurotransmitter receptors and the mechanisms which are obviously important in the central effects of conventional, pharmacologically related drugs. Additional pharmacokinetic data on the brain concentrations of these and other constituents and their metabolites are therefore required for a more meaningful interpretation of the central effects of St. Johns Wort extracts.